Engineered endolysin of Klebsiella pneumoniae phage is a potent and broad-spectrum bactericidal agent against "ESKAPEE" pathogens

The rise of antimicrobial resistance in ESKAPEE pathogens poses significant clinical challenges, especially in polymicrobial infections. Bacteriophage-derived endolysins offer promise in combating this crisis, but face practical hurdles. Our study focuses on engineering endolysins from a phage, fusi...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in microbiology 2024-05, Vol.15, p.1397830-1397830
Main Authors: Chen, Wei, Han, Li-Mei, Chen, Xiu-Zhen, Yi, Peng-Cheng, Li, Hui, Ren, Yun-Yao, Gao, Jing-Han, Zhang, Cai-Yun, Huang, Jing, Wang, Wei-Xiao, Hu, Zhi-Liang, Hu, Chun-Mei
Format: Article
Language:English
Subjects:
ApoE23
COG133
endolysin
engineering
ESKAPEE
Microbiology
polymicrobial infection
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The rise of antimicrobial resistance in ESKAPEE pathogens poses significant clinical challenges, especially in polymicrobial infections. Bacteriophage-derived endolysins offer promise in combating this crisis, but face practical hurdles. Our study focuses on engineering endolysins from a phage, fusing them with ApoE23 and COG133 peptides. We assessed the resulting chimeric proteins' bactericidal activity against ESKAPEE pathogens . ApoE23-Kp84B (CHU-1) reduced over 3 log units of CFU for , , within 1 h, while COG133-Kp84B (CHU-2) showed significant efficacy against . COG133-L1-Kp84B, with a GS linker insertion in CHU-2, exhibited outstanding bactericidal activity against and . Scanning electron microscopy revealed alterations in bacterial morphology after treatment with engineered endolysins. Notably, CHU-1 demonstrated promising anti-biofilm and anti-persister cell activity against and but had limited efficacy in a bacteremia mouse model of their coinfection. Our findings advance the field of endolysin engineering, facilitating the customization of these proteins to target specific bacterial pathogens. This approach holds promise for the development of personalized therapies tailored to combat ESKAPEE infections effectively.
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2024.1397830